NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Por:
Nadal E, Cantero A, Ortega A, Domine M, Barba A, Blasco A, Garcia J, Mosquera J, Vazquez S, Rodriguez D, Lopez-Castro R, Juan Vidal O, Sanchez A, Paz Ares L, Hernandez A, Iranzo P, Diz P, Provencio M, Simo M, Navarro V, Bruna J
Publicada:
1 sep 2022
Resumen:
|